![Joni S. Jacobsen Joni S. Jacobsen](/content/dam/lawyerheadshots/j/joni-jacobsen.jpg/_jcr_content/renditions/joni-jacobsen-square.jpg)
Non-U.S. Issuers Targeted in Securities Class Action Lawsuits Filed in the United States - 2019 Summary
The year 2019 saw an uptick in the number of securities class actions filed against non-U.S. issuers, and substantive trends emerged in the types of cases filed.
![Dechert report on non-U.S. issuers targeted in securities class action lawsuits](/knowledge/publication/2020/3/non-u-s--issuers-targeted-in-securities-class-action-lawsuits-fi/_jcr_content/par/textimage_dechert_co/image.coreimg.jpeg/1583954920146/globe-450.jpeg)
— Six of the non-U.S. issuers against whom securities class actions were filed in 2019 are alleged to have misrepresented the prospects of approval by the U.S. Food and Drug Administration (FDA) and/or compliance with FDA rules and regulations.
— Three of the non-U.S. issuers are alleged to have failed to disclose alleged violations of Chinese government regulations.
— Three of the securities class actions filed against non-U.S. issuers related to alleged bribery schemes.
— Seven of the non-U.S. issuers are alleged to have failed to disclose conflicts of interest that were purportedly relevant to investors.
— Plaintiffs filed a total of 64 securities class action lawsuits against non-U.S. issuers in 2019, compared with 54 in 2018, which our previous report on non-U.S. issuers revealed. The 64 from 2019 accounted for just over 15 percent of the total 404 securities class action lawsuits that year.
Non-U.S. Issuers by Location of Headquarters and/or Principal Place of Business
![Circuit courts where securities class action lawsuits were filed against non-U.S. issuers in 2018](/knowledge/publication/2020/3/non-u-s--issuers-targeted-in-securities-class-action-lawsuits-fi/_jcr_content/par/textimage_dechert_16/image.coreimg.jpeg/1582820937002/2020-02-27-10-56-03-without-title.jpeg)
Of the 64 non-U.S. issuers against whom securities class action complaints were filed in 2019, 18 have corporate headquarters and/or principal places of business in China. Of these 18 companies, 15 are incorporated in the Cayman Islands.
Twelve of the non-U.S. issuers have corporate headquarters and/or principal places of business in the United Kingdom. Nine have corporate headquarters and/or principal places of business in Canada.
With the legalization of recreational marijuana in Canada, six of the Canadian companies against whom securities class actions were brought in 2019 were cannabis-related companies.
Non-U.S. Issuers by Market Capitalization
![](/knowledge/publication/2020/3/non-u-s--issuers-targeted-in-securities-class-action-lawsuits-fi/_jcr_content/par/textimage_dechert/image.coreimg.jpeg/1582821190825/2020-02-27-10-57-30-without-title.jpeg)
The market capitalization of the non-U.S. issuers at the time at which the securities class actions were filed largely consisted of both smaller market cap companies (16 of 64) under US$250 million and larger market cap companies (20 of 64) over US$5 billion.
Non-U.S. Issuers by Industry
![](/knowledge/publication/2020/3/non-u-s--issuers-targeted-in-securities-class-action-lawsuits-fi/_jcr_content/par/textimage_dechert_603230194/image.coreimg.jpeg/1582821582365/2020-02-27-10-57-54-without-title.jpeg)
Other/unknown industries accounted for 35 class action lawsuits filed in 2019 against non-U.S. issuers, followed by the biotechnology and drugs industry, which accounted for 18 such lawsuits filed.